Colon Cancer Biomarker
Colon Cancer Biomarker - Related Videos
28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
0 Views •
Cited by 22 •
2010
Reduced/absent expression of Pms2 and/or ERCC1 in entire crypts is a frequent event within 10 cm on each side of colonic adenocarcinomas, likely the basis of a field defect with high mutability and progression to cancer. Deficiency in Ku86 or CcOI is much less frequent in these field defects.
03:18
Modeling Ovarian Cancer Cell Colonization of Omentum: An Ex Vivo Method to Establish Milky Spot Colonization of Fluorescently Labeled Ovarian Cancer Cells in Murine Omentum Explants
0 Views •
2023
In this video, we establish an ex vivo omental organ culture overlaid with GFP-expressing ovarian cancer cells to study ovarian cancer colonization within the omental explant. This protocol analyzes immune cell structures within the omentum known as milky spots that promote metastases.
13:04
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
0 Views •
Cited by 10 •
2015
We outline a protocol that implements both in vivo and ex vivo approaches to study ovarian cancer colonization of peritoneal adipose tissues, particularly the omentum. Furthermore, we present a protocol to quantitate and analyze immune cell-structures in the omentum known as milky spots, which promote metastases of peritoneal adipose.
05:58
Surgical Trunk Oriented Laparoscopic Right Hemicolectomy (ST-LRH) for Right-Sided Colon Cancer
0 Views •
2025
This protocol describes Surgical Trunk-oriented Laparoscopic Right Hemicolectomy (ST-LRH), a modified laparoscopic right hemicolectomy designed to optimize vascular management and lymph node dissection, simplify surgical procedures, and improve surgical safety and efficiency.
08:55
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
0 Views •
Cited by 111 •
2016
Mice bearing the Colon-26 (C26) carcinoma represent a classical model of cancer cachexia. Progressive muscle wasting occurs in association with tumor growth, over-expression of muscle-specific ubiquitin ligases, and reductions in muscle cross-sectional area. Fat loss is also observed. Cachexia is studied in a time-dependent manner with increasing severity of wasting.
FAQs
A colon cancer biomarker may reflect altered tumor DNA, gene expression, protein production, or cellular behavior. These signals can indicate that a tumor is present, how it behaves, or whether its biology is associated with response to treatment. Considering several marker types helps cancer researchers connect measurable findings with tumor development and therapeutic decision-making.
Markers can be identified in tumor samples or biological fluids, and the source affects what aspect of disease can be examined. Tumor material may provide information about features within the cancer itself, while fluids can support measurement of signals associated with the tumor in a less tissue-centered sample. This distinction matters for diagnosis, monitoring, and research design.
A prognostic use concerns the expected behavior or course of colorectal disease, whereas a treatment-response use concerns whether a tumor’s measurable features are associated with benefit from a therapy. Keeping these purposes separate prevents researchers from treating a marker of disease outcome as though it automatically identifies an appropriate targeted or immune-based treatment.
Usefulness depends on whether the marker reliably connects a measurable feature with a meaningful cancer-related question, such as presence, behavior, prognosis, monitoring, or treatment response. Validation is therefore central: it can determine whether a marker supports more precise treatment decisions, earlier detection, or evaluation of therapy rather than simply describing a molecular or cellular difference.
Researchers examine genetic, molecular, cellular, or protein-based features in tumor samples or biological fluids, then relate those measurements to cancer-related outcomes or treatment response. The investigation may focus on DNA changes, gene-expression patterns, protein production, or interactions between tumor cells and surrounding tissues. This links laboratory observations to diagnostic, prognostic, or therapeutic questions.
Monitoring is relevant when researchers need to evaluate how disease status or therapeutic response changes over time. A marker can be measured in tumor material or biological fluids and interpreted in relation to the tumor’s behavior or response to therapy. In cancer research, this supports more precise assessment of whether an intervention is producing the expected effect.
Biomarkers can help connect an individual tumor’s measurable characteristics with targeted or immune-based treatment choices. Their value lies in matching tumor biology to therapeutic decisions, while validation determines whether that association is dependable. This approach may make treatment selection more precise and can also reveal mechanisms of tumor development that guide further cancer research.
Markers are relevant to early-detection research because measurable features associated with colorectal tumors may help identify tumor presence earlier in the disease process. Their potential value must be established through validation, including whether the signal consistently relates to the tumor. Reliable markers could contribute to earlier detection while also supporting diagnosis and risk assessment.